[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU95108596A - PROTEIN Possessing the ability to inhibit collagen stimulated platelet aggregation and prevent interaction between collagen and vwf, the method of obtaining it - Google Patents

PROTEIN Possessing the ability to inhibit collagen stimulated platelet aggregation and prevent interaction between collagen and vwf, the method of obtaining it

Info

Publication number
RU95108596A
RU95108596A RU95108596/13A RU95108596A RU95108596A RU 95108596 A RU95108596 A RU 95108596A RU 95108596/13 A RU95108596/13 A RU 95108596/13A RU 95108596 A RU95108596 A RU 95108596A RU 95108596 A RU95108596 A RU 95108596A
Authority
RU
Russia
Prior art keywords
collagen
protein
vwf
platelet aggregation
ability
Prior art date
Application number
RU95108596/13A
Other languages
Russian (ru)
Other versions
RU2160280C2 (en
Inventor
Хембергер Юрген
Мельцер Гвидо
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of RU95108596A publication Critical patent/RU95108596A/en
Application granted granted Critical
Publication of RU2160280C2 publication Critical patent/RU2160280C2/en

Links

Claims (9)

1. Белок, обладающий способностью ингибировать стимулированную коллагеном агрегацию тромбоцитов и предотвращать взаимодействие между коллагеном и фактором фон Виллебранда (vWF) и получаемый из слюны медицинских пиявок Hirudo medicinalis.1. A protein with the ability to inhibit collagen-stimulated platelet aggregation and prevent the interaction between collagen and von Willebrand factor (vWF) and derived from the saliva of Hirudo medicinalis medical leeches. 2. Белок по п.1, отличающийся тем, что имеет молекулярную массу 14-15,5 килодальтон. 2. The protein according to claim 1, characterized in that it has a molecular weight of 14-15.5 kilodaltons. 3. Способ получения белка, обладающего способностью ингибировать стимулированную коллагеном агрегацию тромбоцитов и предотвращать взаимодействие между коллагеном и фактором фон Виллебранда (VWF) и имеющего молекулярную массу 14-15,5 килодальтон, отличающийся тем, что его выделяют из слюны медицинских пиявок Hirudo medicinalis и очищают. 3. A method of producing a protein having the ability to inhibit collagen-stimulated platelet aggregation and prevent the interaction between collagen and von Willebrand factor (VWF) and having a molecular weight of 14-15.5 kilodaltons, characterized in that it is isolated from the saliva of medical Hirudo medicinalis leeches and cleaned . 4. Способ по п. 3, отличающийся тем, что белок выделяют из сырого материала в одну стадию препаративным электро- форезом. 4. A method according to claim 3, characterized in that the protein is isolated from the raw material in one step by preparative electrophoresis. 5. Фармацевтический препарат, содержащий активный компонент в сочетании с одним или несколькими носителями, наполнителями или разбавителями, отличающийся тем, что в качестве активного компонента используют белок по п. 1 или 2 в эффективном количестве. 5. A pharmaceutical preparation containing an active component in combination with one or more carriers, excipients or diluents, characterized in that the protein of claim 1 or 2 in an effective amount is used as the active ingredient. 6. Фармацевтический препарат по п. 5, отличающийся тем, что он дополнительно содержит также тромболитическое средство или антикоагулянт. 6. The pharmaceutical preparation according to claim 5, characterized in that it further comprises a thrombolytic agent or anticoagulant. 7. Фармацевтический препарат по п. 5 или 6, в котором носитель представляет собой гелеобразную основу или мазь, отличающийся тем, что он пригоден для покрытия медицинского устройства до его применения. 7. The pharmaceutical preparation according to claim 5 or 6, wherein the carrier is a gel base or ointment, characterized in that it is suitable for coating a medical device prior to use. 8. Имплантируемое или экстракорпоральное медицинское устройство для применения в контакте с жидкостью тела, отличающееся тем, что, с целью придания его поверхности биосовместимости и тромборезистентности, поверхность покрывают иммобилизованным белком по п.1. 8. An implantable or extracorporeal medical device for use in contact with body fluid, characterized in that, in order to impart biocompatibility and thromboresistance to its surface, the surface is coated with an immobilized protein according to claim 1. 9. Способ получения лекарственного средства для предотвращения агрегации тромбоцитов in vitro, in vivo или связывания фактора фон Виллербранда (VWF) с коллагеном in vitro, in vivo и для экстракорпоральных обработок, отличающийся тем, что смешивают белок по п. 1 или 2 с обычно применяемыми носителями, разбавителями, вспомогательными средствами. 9. A method of producing a medicament for preventing platelet aggregation in vitro, in vivo or binding of von Willerbrand factor (VWF) to collagen in vitro, in vivo and for extracorporeal treatments, characterized in that the protein according to claim 1 or 2 is mixed with commonly used carriers, diluents, excipients.
RU95108596/13A 1993-07-01 1994-06-28 PROTEIN CAPABLE ON INHIBITING COLLAGEN STIMULATED AGGREGATION OF THROMBOCYTES AND PREVENTING INTERACTION BETWEEN COLLAGEN AND vWF, METHOD OF PREPARING THEREOF, PHARMACOLOGICAL COMPOSITION BASED THEREON RU2160280C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93110528.2 1993-07-01
EP93110528 1993-07-01

Publications (2)

Publication Number Publication Date
RU95108596A true RU95108596A (en) 1999-01-10
RU2160280C2 RU2160280C2 (en) 2000-12-10

Family

ID=8213032

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95108596/13A RU2160280C2 (en) 1993-07-01 1994-06-28 PROTEIN CAPABLE ON INHIBITING COLLAGEN STIMULATED AGGREGATION OF THROMBOCYTES AND PREVENTING INTERACTION BETWEEN COLLAGEN AND vWF, METHOD OF PREPARING THEREOF, PHARMACOLOGICAL COMPOSITION BASED THEREON

Country Status (22)

Country Link
US (1) US5710131A (en)
EP (1) EP0662088B1 (en)
JP (1) JP3742429B2 (en)
KR (2) KR100455639B1 (en)
CN (1) CN1134451C (en)
AT (1) ATE210679T1 (en)
AU (1) AU680929B2 (en)
CA (1) CA2143416C (en)
CZ (1) CZ287472B6 (en)
DE (1) DE69429419T2 (en)
DK (1) DK0662088T3 (en)
ES (1) ES2169080T3 (en)
HU (1) HU214580B (en)
NO (1) NO320150B1 (en)
PL (1) PL180752B1 (en)
PT (1) PT662088E (en)
RU (1) RU2160280C2 (en)
SK (1) SK282961B6 (en)
TW (1) TW281678B (en)
UA (1) UA41332C2 (en)
WO (1) WO1995001375A1 (en)
ZA (1) ZA944738B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153760B1 (en) * 1998-11-25 2001-07-01 Univ Barcelona Autonoma METALOCARBOXIPEPTIDASAS INHIBITORS AS A FIBRINOLITIC AGENT.
MXPA01009363A (en) * 1999-03-18 2002-06-04 Merck Patent Gmbh Protein for blocking platelet adhesion.
RU2287580C2 (en) 1999-05-07 2006-11-20 Авентис Фарма Дойчланд Гмбх Glycoprotein vi as collagen recombinant receptor on platelets and its using in pharmaceutics
MY128992A (en) 2000-08-25 2007-03-30 Merck Patent Gmbh Saratin for inhibiting platelet adhesion to collagen
GB0031448D0 (en) * 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
CA2579374A1 (en) 2004-09-07 2006-03-30 Archemix Corp. Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
WO2006029258A2 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US20060286548A1 (en) * 2005-06-16 2006-12-21 Gregory Liposky Method of making recombinant human antibodies for use in biosensor technology
CA2623565A1 (en) 2005-09-28 2007-04-05 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
TWI391143B (en) * 2005-11-04 2013-04-01 Otsuka Pharma Co Ltd Platelet aggregation inhibitor composition
US20080015145A1 (en) 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
EP2316465A1 (en) * 2009-10-15 2011-05-04 Centre National De La Recherche Scientifique Use of extract of leeches' saliva as anti-bacterial agent for the manufacture of different compositons
WO2012104866A1 (en) 2011-01-31 2012-08-09 Council Of Scientific & Industrial Research Chiral 1-(4-methylphenylmethyl)-5-oxo-{n-[(3-t-butoxycarbonyl- aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751179T2 (en) * 1986-05-30 1995-07-27 Scripps Research Inst Peptides that inhibit the binding of the Von Willebrand factor.
US5238919A (en) * 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US5256559A (en) * 1988-03-04 1993-10-26 Biogen, Inc. Methods and compositions for inhibiting platelet aggregation
IL86856A0 (en) * 1988-06-24 1988-11-30 Yissum Res Dev Co Bovine xa factor and pharmaceutical compositions containing the same
HUT57060A (en) * 1988-12-05 1991-11-28 Biogen Inc Process for producing compositions for inhibiting blood platelet aggregation
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
CA2052486A1 (en) * 1990-10-09 1992-04-10 Thomas M. Connolly Protein for inhibiting collagen-stimulated platelet aggregation
GB9022040D0 (en) * 1990-10-10 1990-11-21 Biopharm Ltd Platelet adhesion inhibitor
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents

Similar Documents

Publication Publication Date Title
RU95108596A (en) PROTEIN Possessing the ability to inhibit collagen stimulated platelet aggregation and prevent interaction between collagen and vwf, the method of obtaining it
CA2183871A1 (en) Platelet growth accelerator
EP1234586A3 (en) Hepatoselective pharmaceutical actives
IT1142032B (en) HUMAN PROTEIN-BASED BLOOD COAGULATION PREPARATION AND PREPARATION PROCEDURE
EP0372670A3 (en) Hirudin peptides for inhibiting platelet aggregation
DE68911061D1 (en) Means for controlling thrombus formation.
RU93032613A (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PATIENTS WITH PROLONGED COAGULATION TIME, METHOD OF TREATING PATIENTS, USING THE EPI INHIBITOR FOR OBTAINING THE PHARMACEUTICAL PREPARATION
EP0308802A2 (en) Composition for preventing and treating thrombosis, and hemocompatible surgical implant therefor
CA2189947A1 (en) Use of von willebrand factor and pharmaceutical formulation
KR950703004A (en) INHIBITOR OF COLLAGEN-STIMULATED PLATELET AGGREGATION
DK0668077T3 (en) Products containing G-CSF and TNF-binding protein
IT1224574B (en) ACTUATION FACTOR OF NEUTROFILE LEUKOCYTES, PREPARATION PROCEDURE, AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT
NZ230155A (en) N-2,3-butadienyl-n"-substituted-triamindalkanes and alkenes, and pharmaceutical compositions
EP0253146A3 (en) The use of d-fenfluramine for the manufacture of medicaments for treating depression
ATE89737T1 (en) TREATMENT OF LEUKOCYTE DISORDERS WITH GM-CSF.
EP0199117A3 (en) New therapeutical use of phosphocreatine
SE8802805L (en) PHARMACEUTICAL COMPOSITION TO EASY TO CLEAR CARE AND PROCEDURE FOR THE PREPARATION OF THE SAME
ES2182840T3 (en) FACTOR XIII FOR THE TREATMENT OF SKIN WOUNDS.
NO873934L (en) SPECIAL SEROTONINANTAGONISTIC RELATIONSHIP.
CA2036592A1 (en) Therapeutic agent for diabetic gangrene
ATE100332T1 (en) PHARMACEUTICAL COMPOSITION USABLE IN THE TREATMENT OF CARDIAC DISEASES.
DK417889A (en) USE OF 2-AZABICYCLO (2.2.2.) - CARBOXYLIC ACID DERIVATIVES FOR THE MANUFACTURE OF MEDICAL PRODUCTS FOR THE TREATMENT OF VASCULAR DISEASES
RU93015924A (en) METHOD OF TREATMENT OF TROPHIC ULCERS OF THE LOWER EXTREMITIES
RU93016030A (en) A MEDICINE STIMULATING THE GRANULOSITARY GROWTH OF HEMATOPHONYA IN CYTOSTATIC MYELODEPRESSIONS